

*Billion Reach  
Zillion Smiles*

# HETERO

Corporate Presentation 2026

API | FDF | Biosimilars | CDMO

[www.hetero.com](http://www.hetero.com)



*Billion Reach  
Zillion Smiles*

## **Hetero** - The promise of a **healthier world**

- 
- India's leading **generic pharmaceutical** company
  - World's largest producer of **anti-retroviral drugs**
  - **A trusted partner** of choice to multi-national pharma companies and global procurement bodies





*Billion Reach*  
*Zillion Smiles*

Purpose that drives us  
**Inspiring Human Belief in a Healthier World**

---

Belief that powers us  
**Transforming science and technology  
into therapies for a healthier world**

---

Values that set us apart



**Knowledge**



**Integrity**



**Trust**



**Agility**



*Billion Reach*  
*Zillion Smiles*



**Dr. Bandi Parthasaradhi Reddy**

Chairman

Hetero Group of Companies

## **Legacy** - A passion for a **healthier world**

- Championing **accessibility** and **affordability** of life-saving medicines across geographies.
- **A 30+ year legacy** of delivering life-saving medicines to everyone everywhere



# 30+ years of advancing life-saving care

**Billion** Reach  
**Zillion** Smiles



**1993**  
**Our humble beginnings**



**1994**  
Commenced production at our first API manufacturing unit in Hyderabad



**1995**  
Established the Hetero Research Foundation (HRF)



**1997**  
Emerged as one of the leading companies offering affordable ARVs & APIs



**1998**  
HRF received accolades for developing generic processes for **more than 20 APIs** within 3 years of its inception



**2001**  
Received first **USFDA approval** for API manufacturing facility in Hyderabad



**2017**  
Received **DCGI approval** for the Hepatitis C fixed-dose combination drug **Velasof**



**2016**  
Launched the third biosimilar product, **Bevacizumab**



**2015**  
Launched biosimilar products **Darbepoetin Alfa & Rituximab**; also became the first company in India to launch the fixed-dose combination **Ledipasvir + Sofosbuvir**



**2014**  
Launched the blockbuster Hepatitis C drug **Sofosbuvir**



**2009**  
Set up a dedicated biological manufacturing unit in Hyderabad



**2007**  
Established **Asia's largest SEZ complex** for **API manufacturing** in Visakhapatnam



**2006**  
Received **USFDA approval** for a finished dosage facility in Hyderabad



**2005**  
Emerged as one of the first companies in India to produce **Oseltamivir** for the treatment of bird flu and swine flu



**2018**  
Hetero's European subsidiary **Amarox**, acquired **Tarbis Farma, S.L.U.**



**2020**  
Launched the first generic **Remdesivir** in **India** for the treatment of COVID-19



**2021**  
Acquired a manufacturing facility in **Vemgal, Karnataka**, from **GSK**



**2022**  
Received DCGI approval to manufacture COVID-19 drug, **Paxlovid**

 **Unveiled a new corporate identity**



**2023**  
Celebrated **30 years** of Hetero's journey - from humble beginnings to a **global pharmaceutical leader**



**2024**  
Entered into a partnership with **Gilead Sciences** to expand **Lenacapavir** availability across **120 high-incidence countries**, supporting the **global HIV response**.



**2025**  
**Opened a new office** in **Warsaw, Poland**, marking Hetero's entry into the **Eastern Europe market**.



**2026**  
Launched generic **semaglutide** in emerging markets under the brand names **Truglyx, Rolmodi and Moto G**  
Continues its journey into the **4<sup>th</sup> decade** - **Inspiring human belief in a healthier world**



Billion Reach  
Zillion Smiles

# At a glance

Serving communities across geographies with unparalleled strengths in pharmaceutical research, manufacturing, and marketing

**50+** strategically located marketing offices

**36+** API, FDF & Biosimilars manufacturing facilities

**450+** APIs life-saving treatments for every

**6** world-class R&D centers

**550+** FDFs health concern

**2,000+** scientists

**Asia's largest** SEZ complex for API manufacturing

**145+** Countries with established commercial presence

## Global Marketing Arms

**Amarox**  
Europe & GCC

**CAMBER**  
PHARMACEUTICALS, INC.  
US & SEA

**HETERO**  
HEALTHCARE  
India

**SEVEN**  
PHARMA  
LATAM





Billion Reach  
Zillion Smiles

# A healthier world made possible

Across **145+** countries, we advance healthcare by ensuring access to affordable and high-quality medicines.



EUROPE	CIS COUNTRIES	AFRICA	NORTH AMERICA	ASIA	MIDDLE EAST	CENTRAL AMERICA	SOUTH AMERICA	AUSTRALIA	
<ul style="list-style-type: none"> <li>Germany</li> <li>Netherlands</li> <li>Poland</li> <li>Spain</li> <li>UK</li> </ul>	<ul style="list-style-type: none"> <li>Ukraine</li> <li>Kyrgyzstan</li> <li>Uzbekistan</li> <li>Kazakhstan</li> <li>Russia</li> </ul>	<ul style="list-style-type: none"> <li>Algeria</li> <li>Egypt</li> <li>Kenya</li> <li>Nigeria</li> <li>South Africa</li> </ul>	<ul style="list-style-type: none"> <li>Canada</li> <li>USA</li> </ul>	<ul style="list-style-type: none"> <li>Cambodia</li> <li>China</li> <li>India</li> <li>Indonesia</li> <li>Japan</li> <li>Malaysia</li> <li>Myanmar</li> </ul>	<ul style="list-style-type: none"> <li>Philippines</li> <li>Singapore</li> <li>South Korea</li> <li>Taiwan</li> <li>Thailand</li> <li>Vietnam</li> </ul>	<ul style="list-style-type: none"> <li>UAE</li> <li>Saudi Arabia</li> </ul>	<ul style="list-style-type: none"> <li>Costa Rica</li> <li>El Salvador</li> <li>Guatemala</li> <li>Honduras</li> <li>Mexico</li> <li>Nicaragua</li> <li>Panama</li> </ul>	<ul style="list-style-type: none"> <li>Brazil</li> <li>Chile</li> <li>Colombia</li> <li>Ecuador</li> <li>Paraguay</li> <li>Peru</li> <li>Venezuela</li> </ul>	<ul style="list-style-type: none"> <li>Australia</li> </ul>

### CARIBBEAN

- Dominican Republic

● Branch office/ Subsidiary  
 ■ Manufacturing facility



*Billion Reach*  
*Zillion Smiles*

# Our **People**, Our **Strength**

---

**ZOOK+**

Hetero Global Family united by passion, purpose and performance

Hetero's strength lies in our people who are

**Limitless. Believers. Committed. Passionate**





*Billion Reach  
Zillion Smiles*

# Promise of a clean, green, and healthier world

**Sustainability is at the core of Hetero's growth and purpose.**

Through responsible operations, environmental stewardship, and strong governance, we strive to create lasting value for the environment, our people, and the communities we serve.

**Our sustainability framework is built around three core pillars:**



## **Environmental Commitment**

Reducing emissions, conserving natural resources, and improving process efficiency through green chemistry and energy optimization.

- Emissions Management
- Water Stewardship • Green Chemistry
- Energy Efficiency • Circular Economy
- Sustainable Packaging



## **Social Performance**

Prioritizing employee well-being, health and safety, diversity, and community development.

- Workforce Development & Well-Being • Diversity & Inclusion
- Human Rights & Ethical Practices
- Health, Safety & Compliance



## **Governance & Accountability**

Ensuring integrity, compliance, and transparency across our operations and supply chain.

- Sustainable Supply Chain Oversight
- Ethics & Integrity • Data Privacy & Cybersecurity • Risk Management & Business Resilience



*Billion Reach  
Zillion Smiles*

# Promise of a clean, green, and healthier world

## Carbon Reduction Plan

Hetero's Carbon Reduction Plan reflects our long-term commitment to achieving Net Zero emissions

through a structured and measurable approach. We systematically track our carbon footprint and implement targeted strategies to progressively reduce operational emissions across our facilities.

## Aspiring to Achieve Net Zero by 2045

- Reduce Scope 1 and Scope 2 carbon emissions by 25% by 2030 (baseline: 2022).
- Increase the share of renewable energy to 30% by 2030.
- Improve wastewater recycling by 5% each year.
- Achieve zero waste to landfill status by 2030.



Committed to the Science Based Targets initiative (SBTi) to achieve net-zero emissions, aligning with global climate action goals



Silver Medal rating — among the top 15% companies assessed globally by EcoVadis.



Hetero is a signatory to the UNGC, incorporating their 10 principles on human rights, labour, environment, and anti-corruption.



*Billion Reach  
Zillion Smiles*

# Promise of an equitable and healthier world

## Building Sustainable Communities Through Responsible Action

Hetero's Corporate Social Responsibility (CSR) is guided by a strong commitment to building sustainable and inclusive communities by addressing critical development needs with compassion, equity, and a spirit of service. Our initiatives take a holistic approach, focusing on key areas such as healthcare, education, environmental stewardship, livelihoods, and cultural preservation.



Community Health



Education



Water, Sanitation and Hygiene



Livelihoods



Climate Response



Community Infrastructure



# Promise of a **compassionate and healthier world**

Inspired by **Dr. Bandi Parthasaradhi Reddy's** (Chairman - Hetero Group of companies) philanthropic vision, Sindhu Hospitals extends Hetero's 30-year legacy of innovative and compassionate healthcare. With main focus on oncology and supported by world-renowned specialists, the hospital combines cutting-edge technology with personalized care, redefining the treatment of critical illnesses and elevating healthcare standards.

As part of **Hetero's Corporate Social Responsibility (CSR) commitment**, Sindhu Hospitals, a not-for-profit yet premium healthcare facility, is dedicated to providing world-class healthcare to underserved communities, ensuring that both life-saving medicines and health are accessible to all, regardless of socioeconomic status.



**1500**  
Beds

**720+**  
Doctors

**2700+**  
Nurses

**4800+**  
Paramedics & Others

**Free / Subsidized Treatment**  
for underserved patients

\*Estimated strength when hospital facility is fully operational.



Billion *Reach*  
Zillion *Smiles*

# Strategic Channels

API | FDF | Biosimilars | CDMO

Global Access





*Billion Reach  
Zillion Smiles*

# API - A healthier world made accessible

- Pioneer in developing and manufacturing affordable **APIs for ARVs**
- Leading producer of **bulk drugs to generic manufacturers**

**450+** APIs  
in multiple therapeutic areas

Reactor volume  
**7,000+** KL per annum

**15** Production facilities  
across the globe

Installed capacity  
**36,000+** MT per annum



**Asia's largest SEZ complex**  
for API manufacturing



Billion Reach  
Zillion Smiles

# FDF - A healthier world made possible, dose by dose

- Global leader in manufacturing branded and non-branded generics
- Pioneer in manufacturing affordable drugs for life-threatening diseases like **HIV/AIDS, Hepatitis C, Bird Flu, and Swine Flu, COVID-19.**

**23**  
**advanced facilities** producing globally approved generics

**Tablets**  
**50** billion+ units per annum

**Liquids**  
**20** million+ units per annum

**35+**  
**Oncology Products**

**Injectables\***  
**180** million+ units per annum  
\*Includes lyophilised, liquids and powder

**Capsules**  
**10** billion+ units per annum

**3**  
**dedicated facilities** for cancer treatment drugs

**Pellets**  
**360** tonnes+ per annum



*Billion Reach  
Zillion Smiles*

# Biosimilars - A healthier world made **affordable**

- PICS accredited manufacturing facilities
- Backed by strong R&D and cutting-edge technology
- A dedicated Biopharma arm for high-quality, cost-effective and fast production of biosimilars

**9**

Biosimilars **launched**

**Bioreactor** capacities

**5** KL+

**8**

under development

**Batches** produced

**135+** per annum

**45+** Countries

with marketing presence

**Formulation manufacturing**

**PFS 75** million+  
units per annum

**Vials 60** million+  
units per annum



*Billion Reach  
Zillion Smiles*

# CDMO - Advancing a healthier world through **custom manufacturing**

**One-stop CDMO solution** in drug life-cycle for APIs, Formulations and Biosimilars from pre-clinical to commercial supply

**Delivering end-to-end contract R&D** – from clinical supply and commercial scale-up to seamless technology transfer

## **Trusted partner for CMO/CDMO solutions**

With significant economy-of-scale advantage and backward-integration capabilities, makes Hetero a reliable and value-driven CMO/CDMO partner.

KSMs, RSMs, APIs | FDF | HP Handling | Supply Security

**30+** years of inclusive pharmaceutical excellence

**20+** years of unparalleled CMO/CDMO experience

**Drug Substance & Drug Products**



*Billion Reach*  
*Zillion Smiles*

# Global Access - Delivering critical drugs for a healthier world



Among the first to introduce life-saving hepatitis drugs through strategic global licensing agreements.

Introduced first-line and second line antiretroviral regimens, and protease inhibitors for treating and preventing HIV infection.

Geared up to launch long-acting antiretroviral products with the potential to transform HIV prevention and treatment approaches.

**120+** Countries  
with marketing presence

**2000+** Product registrations  
with local regulatory authorities



*Billion Reach  
Zillion Smiles*

# R&D - Advancing product development for a **Healthier World**

Driving innovation across APIs, formulations, custom synthesis, contract research, analytical sciences, packaging, IP, technology transfer, and quality assurance.

- Innovative, safe, sustainable, and cost-efficient technologies and processes
- Continuous investment to accelerate development of affordable APIs, formulations, and biosimilars
- Focused on first-to-market, fast-to-market, and complex specialty therapeutics

**6** world-class R&D centers

**2000+** scientists

**300+** products commercialized since 1995

**35%** of investments dedicated to R&D



# Targeting multiple **therapy areas** for a **healthier world**

*Billion Reach*  
*Zillion Smiles*



Allergy



Autoimmune  
Disorders



Cardiovascular



COVID-19



Diabetes



Gastroenterology



Haematology



Hepatitis



HIV/AIDS



Immunology



Malaria



Neurology



Oncology



Ophthalmology



Respiratory



Urology



*Billion Reach*  
*Zillion Smiles*

# Global standards for a healthier world

Our manufacturing facilities adhere to rigorous quality framework and assurance procedures in line with **global regulatory standards**. Stringent operating procedures and compliance to **current Good Manufacturing Practices** (cGMP) and applicable regulatory requirements.

## Global Regulatory Approvals

**CDSCO** - India | **FDA** - US | **PMDA** - Japan

**GMP** - EU | **MHRA** - UK | **SAHPRA** - South Africa

**ANVISA** - Brazil | **INVIMA** - Colombia | **MOH** - Russia

**COFEPRIS** - Mexico | **GCC** - DR | **MFDS** - South Korea

**TGA** - Australia | **PIC/S**






*Billion Reach  
Zillion Smiles*

# State-of-the-art **manufacturing sites** for a **healthier world**

- Large manufacturing facilities equipped to deliver on any scale in quick time
- Stringent operating procedures and compliance to current Good Manufacturing Practices (cGMP) and applicable regulatory requirements

## API Facilities in India



## Formulation Facilities in India



## Biosimilars





*Billion Reach  
Zillion Smiles*

## Overseas manufacturing facilities





Inspiring Human Belief  
in a Healthier World

**Hetero Corporate**

Floor 9-11, Tower 30, RMZ Nexity, Sy. No. 83/1, Knowledge City, Raidurg, Hyderabad - 500081, Telangana, India